SHANGHAI, May 21 /PRNewswire/ -- Policies of the new health reform in China have been released after deep consideration and discussion, among which is one of the most important policies 'The National Essential Drug System'. The purpose of this policy is to solve the high cost of drugs in China through a government-initiated program. Ideally the program will lower the drug prices that cover a wide range of diseases and meet the majority's basic medical needs.
In essence, the policy states that the provincial government organizes the public bidding to choose the drug suppliers and distributors. The reference price is set by the central government and finalized by the provincial government according to the bidding result. National essential drugs should be available in all healthcare institutes and drug retailers but not necessarily 100% used, where the usage rate will be further ruled by the healthcare administration.
According to Kitty Lu, Consulting Manager of Pharmaceuticals practice, Frost & Sullivan China, the healthcare reform will accelerate the centralization of the generic pharmaceutical market.
For generics, being listed as a national essential drug incurs the paradox of a lower price and higher sales. The price is expected to decrease by 20%-25%, while the increase of sales is dependent on the execution of this policy, which Frost & Sullivan is optimistic about as it is one of the most important parts of this new health reform.
Under this assumption, generics with small sales if included in the essential drug list will have a little space to increase but will definitely decrease if not on the list, causing a dilemma for small generic suppliers. It is expected that 1/3 of the small generic suppliers who lack efficient distribution channels and high-quality products will be pushed out of the market in 3-5 years after the policy's execution. In contrast, the policy will largely boost the increase of products by large generic suppliers; make them stronger even with a lower price.
As a result, the market leaders become even stronger while the smaller players fall behind, accelerating the centralization of the generic pharmaceutical market.
In addition, it has been reported that the draft of "Regulation for Drug Price Administration" is completed and drugs of certain kind, such as patent drugs and first-generics, enjoy preferential policies of individual pricing. This means there is no price change or little change even if listed in the national essential drug list.
"The policy is not finalized but it is very likely to come true since it is highly consistent with the long-implementing policy of encouraging innovation." Kitty concludes, "Such policy enables the listing of national essential drug with little or even no depreciation of patent and first generics which greatly benefits the drug supplier by a huge increase in sales volume. Drug innovation is thus expected to be promoted partly by the new policies for greater profit."
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best in class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best practice models to drive the generation, evaluation and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 35 offices on six continents. To join our Growth Partnership, please visit http://www.frost.com.
Media Contact: Riona Jin Corporate Communications - China P: +86 21 5407 5783 Ext 8652 M: +86 139 169 87828 E: firstname.lastname@example.org
|SOURCE Frost & Sullivan|
Copyright©2009 PR Newswire.
All rights reserved